Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation

Aes Simões, D. M. Pereira, S. E. Gomes, H. Brito, T. Carvalho, A. French, R. E. Castro, Clifford J Steer, S. N. Thibodeau, C. M.P. Rodrigues, P. M. Borralho

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

This study was designed to evaluate MEK5 and ERK5 expression in colon cancer progression and to ascertain the relevance of MEK5/ERK5 signalling in colon cancer. Expression of MEK5 and ERK5 was evaluated in 323 human colon cancer samples. To evaluate the role of MEK5/ERK5 signalling in colon cancer, we developed a stable cell line model with differential MEK5/ERK5 activation. Impact of differential MEK5/ERK5 signalling was evaluated on cell cycle progression by flow cytometry and cell migration was evaluated by wound healing and transwell migration assays. Finally, we used an orthotopic xenograft mouse model of colon cancer to assess tumour growth and progression. Our results demonstrated that MEK5 and ERK5 are overexpressed in human adenomas (P<0.01) and adenocarcinomas (P<0.05), where increased ERK5 expression correlated with the acquisition of more invasive and metastatic potential (P<0.05). Interestingly, we observed a significant correlation between ERK5 expression and NF-κB activation in human adenocarcinomas (P<0.001). We also showed that ERK5 overactivation significantly accelerated cell cycle progression (P<0.05) and increased cell migration (P<0.01). Furthermore, cells with overactivated ERK5 displayed increased NF-κB nuclear translocation and transcriptional activity (P<0.05), together with increased expression of the mesenchymal marker vimentin (P<0.05). We further demonstrated that increased NF-κB activation was associated with increased IκB phosphorylation and degradation (P<0.05). Finally, in the mouse model, lymph node metastasis was exclusively seen in orthotopically implanted tumours with overactivated MEK5/ERK5, and not in tumours with inhibited MEK5/ERK5. Our results suggested that MEK5/ERK5/NF-κB signalling pathway is important for tumour onset, progression and metastasis, possibly representing a novel relevant therapeutic target in colon cancer treatment.

Original languageEnglish (US)
Article numbere1718
JournalCell Death and Disease
Volume6
Issue number4
DOIs
StatePublished - Apr 9 2015

Fingerprint

Colonic Neoplasms
Cell Movement
Neoplasms
Cell Cycle
Adenocarcinoma
Neoplasm Metastasis
Vimentin
Heterografts
Adenoma
Wound Healing
Flow Cytometry
Lymph Nodes
Phosphorylation
Cell Line
Growth

Cite this

Simões, A., Pereira, D. M., Gomes, S. E., Brito, H., Carvalho, T., French, A., ... Borralho, P. M. (2015). Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. Cell Death and Disease, 6(4), [e1718]. https://doi.org/10.1038/cddis.2015.83

Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. / Simões, Aes; Pereira, D. M.; Gomes, S. E.; Brito, H.; Carvalho, T.; French, A.; Castro, R. E.; Steer, Clifford J; Thibodeau, S. N.; Rodrigues, C. M.P.; Borralho, P. M.

In: Cell Death and Disease, Vol. 6, No. 4, e1718, 09.04.2015.

Research output: Contribution to journalArticle

Simões, A, Pereira, DM, Gomes, SE, Brito, H, Carvalho, T, French, A, Castro, RE, Steer, CJ, Thibodeau, SN, Rodrigues, CMP & Borralho, PM 2015, 'Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation', Cell Death and Disease, vol. 6, no. 4, e1718. https://doi.org/10.1038/cddis.2015.83
Simões, Aes ; Pereira, D. M. ; Gomes, S. E. ; Brito, H. ; Carvalho, T. ; French, A. ; Castro, R. E. ; Steer, Clifford J ; Thibodeau, S. N. ; Rodrigues, C. M.P. ; Borralho, P. M. / Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. In: Cell Death and Disease. 2015 ; Vol. 6, No. 4.
@article{030cd5037fb94348a22c261fadd2a959,
title = "Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation",
abstract = "This study was designed to evaluate MEK5 and ERK5 expression in colon cancer progression and to ascertain the relevance of MEK5/ERK5 signalling in colon cancer. Expression of MEK5 and ERK5 was evaluated in 323 human colon cancer samples. To evaluate the role of MEK5/ERK5 signalling in colon cancer, we developed a stable cell line model with differential MEK5/ERK5 activation. Impact of differential MEK5/ERK5 signalling was evaluated on cell cycle progression by flow cytometry and cell migration was evaluated by wound healing and transwell migration assays. Finally, we used an orthotopic xenograft mouse model of colon cancer to assess tumour growth and progression. Our results demonstrated that MEK5 and ERK5 are overexpressed in human adenomas (P<0.01) and adenocarcinomas (P<0.05), where increased ERK5 expression correlated with the acquisition of more invasive and metastatic potential (P<0.05). Interestingly, we observed a significant correlation between ERK5 expression and NF-κB activation in human adenocarcinomas (P<0.001). We also showed that ERK5 overactivation significantly accelerated cell cycle progression (P<0.05) and increased cell migration (P<0.01). Furthermore, cells with overactivated ERK5 displayed increased NF-κB nuclear translocation and transcriptional activity (P<0.05), together with increased expression of the mesenchymal marker vimentin (P<0.05). We further demonstrated that increased NF-κB activation was associated with increased IκB phosphorylation and degradation (P<0.05). Finally, in the mouse model, lymph node metastasis was exclusively seen in orthotopically implanted tumours with overactivated MEK5/ERK5, and not in tumours with inhibited MEK5/ERK5. Our results suggested that MEK5/ERK5/NF-κB signalling pathway is important for tumour onset, progression and metastasis, possibly representing a novel relevant therapeutic target in colon cancer treatment.",
author = "Aes Sim{\~o}es and Pereira, {D. M.} and Gomes, {S. E.} and H. Brito and T. Carvalho and A. French and Castro, {R. E.} and Steer, {Clifford J} and Thibodeau, {S. N.} and Rodrigues, {C. M.P.} and Borralho, {P. M.}",
year = "2015",
month = "4",
day = "9",
doi = "10.1038/cddis.2015.83",
language = "English (US)",
volume = "6",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation

AU - Simões, Aes

AU - Pereira, D. M.

AU - Gomes, S. E.

AU - Brito, H.

AU - Carvalho, T.

AU - French, A.

AU - Castro, R. E.

AU - Steer, Clifford J

AU - Thibodeau, S. N.

AU - Rodrigues, C. M.P.

AU - Borralho, P. M.

PY - 2015/4/9

Y1 - 2015/4/9

N2 - This study was designed to evaluate MEK5 and ERK5 expression in colon cancer progression and to ascertain the relevance of MEK5/ERK5 signalling in colon cancer. Expression of MEK5 and ERK5 was evaluated in 323 human colon cancer samples. To evaluate the role of MEK5/ERK5 signalling in colon cancer, we developed a stable cell line model with differential MEK5/ERK5 activation. Impact of differential MEK5/ERK5 signalling was evaluated on cell cycle progression by flow cytometry and cell migration was evaluated by wound healing and transwell migration assays. Finally, we used an orthotopic xenograft mouse model of colon cancer to assess tumour growth and progression. Our results demonstrated that MEK5 and ERK5 are overexpressed in human adenomas (P<0.01) and adenocarcinomas (P<0.05), where increased ERK5 expression correlated with the acquisition of more invasive and metastatic potential (P<0.05). Interestingly, we observed a significant correlation between ERK5 expression and NF-κB activation in human adenocarcinomas (P<0.001). We also showed that ERK5 overactivation significantly accelerated cell cycle progression (P<0.05) and increased cell migration (P<0.01). Furthermore, cells with overactivated ERK5 displayed increased NF-κB nuclear translocation and transcriptional activity (P<0.05), together with increased expression of the mesenchymal marker vimentin (P<0.05). We further demonstrated that increased NF-κB activation was associated with increased IκB phosphorylation and degradation (P<0.05). Finally, in the mouse model, lymph node metastasis was exclusively seen in orthotopically implanted tumours with overactivated MEK5/ERK5, and not in tumours with inhibited MEK5/ERK5. Our results suggested that MEK5/ERK5/NF-κB signalling pathway is important for tumour onset, progression and metastasis, possibly representing a novel relevant therapeutic target in colon cancer treatment.

AB - This study was designed to evaluate MEK5 and ERK5 expression in colon cancer progression and to ascertain the relevance of MEK5/ERK5 signalling in colon cancer. Expression of MEK5 and ERK5 was evaluated in 323 human colon cancer samples. To evaluate the role of MEK5/ERK5 signalling in colon cancer, we developed a stable cell line model with differential MEK5/ERK5 activation. Impact of differential MEK5/ERK5 signalling was evaluated on cell cycle progression by flow cytometry and cell migration was evaluated by wound healing and transwell migration assays. Finally, we used an orthotopic xenograft mouse model of colon cancer to assess tumour growth and progression. Our results demonstrated that MEK5 and ERK5 are overexpressed in human adenomas (P<0.01) and adenocarcinomas (P<0.05), where increased ERK5 expression correlated with the acquisition of more invasive and metastatic potential (P<0.05). Interestingly, we observed a significant correlation between ERK5 expression and NF-κB activation in human adenocarcinomas (P<0.001). We also showed that ERK5 overactivation significantly accelerated cell cycle progression (P<0.05) and increased cell migration (P<0.01). Furthermore, cells with overactivated ERK5 displayed increased NF-κB nuclear translocation and transcriptional activity (P<0.05), together with increased expression of the mesenchymal marker vimentin (P<0.05). We further demonstrated that increased NF-κB activation was associated with increased IκB phosphorylation and degradation (P<0.05). Finally, in the mouse model, lymph node metastasis was exclusively seen in orthotopically implanted tumours with overactivated MEK5/ERK5, and not in tumours with inhibited MEK5/ERK5. Our results suggested that MEK5/ERK5/NF-κB signalling pathway is important for tumour onset, progression and metastasis, possibly representing a novel relevant therapeutic target in colon cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=84989924728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989924728&partnerID=8YFLogxK

U2 - 10.1038/cddis.2015.83

DO - 10.1038/cddis.2015.83

M3 - Article

C2 - 25855966

AN - SCOPUS:84989924728

VL - 6

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 4

M1 - e1718

ER -